1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sustained Release Injectables Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Microparticles
1.2.3 Implants
1.2.4 Gels
1.3 Market by Application
1.3.1 Global Sustained Release Injectables Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Diabetes
1.3.3 Leukemia
1.3.4 Acromegaly
1.3.5 Ophthalmology
1.3.6 CNS
1.3.7 Rheumatology
1.3.8 Oncology
1.3.9 Reproductive Health
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Sustained Release Injectables Market Perspective (2017-2028)
2.2 Sustained Release Injectables Growth Trends by Region
2.2.1 Sustained Release Injectables Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Sustained Release Injectables Historic Market Size by Region (2017-2022)
2.2.3 Sustained Release Injectables Forecasted Market Size by Region (2023-2028)
2.3 Sustained Release Injectables Market Dynamics
2.3.1 Sustained Release Injectables Industry Trends
2.3.2 Sustained Release Injectables Market Drivers
2.3.3 Sustained Release Injectables Market Challenges
2.3.4 Sustained Release Injectables Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Sustained Release Injectables Players by Revenue
3.1.1 Global Top Sustained Release Injectables Players by Revenue (2017-2022)
3.1.2 Global Sustained Release Injectables Revenue Market Share by Players (2017-2022)
3.2 Global Sustained Release Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sustained Release Injectables Revenue
3.4 Global Sustained Release Injectables Market Concentration Ratio
3.4.1 Global Sustained Release Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sustained Release Injectables Revenue in 2021
3.5 Sustained Release Injectables Key Players Head office and Area Served
3.6 Key Players Sustained Release Injectables Product Solution and Service
3.7 Date of Enter into Sustained Release Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Sustained Release Injectables Breakdown Data by Type
4.1 Global Sustained Release Injectables Historic Market Size by Type (2017-2022)
4.2 Global Sustained Release Injectables Forecasted Market Size by Type (2023-2028) 5 Sustained Release Injectables Breakdown Data by Application
5.1 Global Sustained Release Injectables Historic Market Size by Application (2017-2022)
5.2 Global Sustained Release Injectables Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Sustained Release Injectables Market Size (2017-2028)
6.2 North America Sustained Release Injectables Market Size by Country (2017-2022)
6.3 North America Sustained Release Injectables Market Size by Country (2023-2028)
6.4 United States
6.5 Canada 7 Europe
7.1 Europe Sustained Release Injectables Market Size (2017-2028)
7.2 Europe Sustained Release Injectables Market Size by Country (2017-2022)
7.3 Europe Sustained Release Injectables Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Sustained Release Injectables Market Size (2017-2028)
8.2 Asia-Pacific Sustained Release Injectables Market Size by Country (2017-2022)
8.3 Asia-Pacific Sustained Release Injectables Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia 9 Latin America
9.1 Latin America Sustained Release Injectables Market Size (2017-2028)
9.2 Latin America Sustained Release Injectables Market Size by Country (2017-2022)
9.3 Latin America Sustained Release Injectables Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Sustained Release Injectables Market Size (2017-2028)
10.2 Middle East & Africa Sustained Release Injectables Market Size by Country (2017-2022)
10.3 Middle East & Africa Sustained Release Injectables Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE 11 Key Players Profiles
11.1 AntriaBio
11.1.1 AntriaBio Company Detail
11.1.2 AntriaBio Business Overview
11.1.3 AntriaBio Sustained Release Injectables Introduction
11.1.4 AntriaBio Revenue in Sustained Release Injectables Business (2017-2022)
11.1.5 AntriaBio Recent Development
11.2 Ascendis Pharma
11.2.1 Ascendis Pharma Company Detail
11.2.2 Ascendis Pharma Business Overview
11.2.3 Ascendis Pharma Sustained Release Injectables Introduction
11.2.4 Ascendis Pharma Revenue in Sustained Release Injectables Business (2017-2022)
11.2.5 Ascendis Pharma Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Sustained Release Injectables Introduction
11.3.4 AstraZeneca Revenue in Sustained Release Injectables Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Aurobindo
11.4.1 Aurobindo Company Detail
11.4.2 Aurobindo Business Overview
11.4.3 Aurobindo Sustained Release Injectables Introduction
11.4.4 Aurobindo Revenue in Sustained Release Injectables Business (2017-2022)
11.4.5 Aurobindo Recent Development
11.5 Avadel
11.5.1 Avadel Company Detail
11.5.2 Avadel Business Overview
11.5.3 Avadel Sustained Release Injectables Introduction
11.5.4 Avadel Revenue in Sustained Release Injectables Business (2017-2022)
11.5.5 Avadel Recent Development
11.6 Alkermes
11.6.1 Alkermes Company Detail
11.6.2 Alkermes Business Overview
11.6.3 Alkermes Sustained Release Injectables Introduction
11.6.4 Alkermes Revenue in Sustained Release Injectables Business (2017-2022)
11.6.5 Alkermes Recent Development
11.7 Amylin Pharmaceuticals
11.7.1 Amylin Pharmaceuticals Company Detail
11.7.2 Amylin Pharmaceuticals Business Overview
11.7.3 Amylin Pharmaceuticals Sustained Release Injectables Introduction
11.7.4 Amylin Pharmaceuticals Revenue in Sustained Release Injectables Business (2017-2022)
11.7.5 Amylin Pharmaceuticals Recent Development
11.8 Biomarin
11.8.1 Biomarin Company Detail
11.8.2 Biomarin Business Overview
11.8.3 Biomarin Sustained Release Injectables Introduction
11.8.4 Biomarin Revenue in Sustained Release Injectables Business (2017-2022)
11.8.5 Biomarin Recent Development
11.9 Camurus
11.9.1 Camurus Company Detail
11.9.2 Camurus Business Overview
11.9.3 Camurus Sustained Release Injectables Introduction
11.9.4 Camurus Revenue in Sustained Release Injectables Business (2017-2022)
11.9.5 Camurus Recent Development
11.10 Critical Pharmaceuticals
11.10.1 Critical Pharmaceuticals Company Detail
11.10.2 Critical Pharmaceuticals Business Overview
11.10.3 Critical Pharmaceuticals Sustained Release Injectables Introduction
11.10.4 Critical Pharmaceuticals Revenue in Sustained Release Injectables Business (2017-2022)
11.10.5 Critical Pharmaceuticals Recent Development
11.11 Durect
11.11.1 Durect Company Detail
11.11.2 Durect Business Overview
11.11.3 Durect Sustained Release Injectables Introduction
11.11.4 Durect Revenue in Sustained Release Injectables Business (2017-2022)
11.11.5 Durect Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Sustained Release Injectables Introduction
11.12.4 Eli Lilly Revenue in Sustained Release Injectables Business (2017-2022)
11.12.5 Eli Lilly Recent Development
11.13 Enzon
11.13.1 Enzon Company Detail
11.13.2 Enzon Business Overview
11.13.3 Enzon Sustained Release Injectables Introduction
11.13.4 Enzon Revenue in Sustained Release Injectables Business (2017-2022)
11.13.5 Enzon Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Sustained Release Injectables Introduction
11.14.4 Ipsen Revenue in Sustained Release Injectables Business (2017-2022)
11.14.5 Ipsen Recent Development
11.15 InnoCore Pharmaceuticals
11.15.1 InnoCore Pharmaceuticals Company Detail
11.15.2 InnoCore Pharmaceuticals Business Overview
11.15.3 InnoCore Pharmaceuticals Sustained Release Injectables Introduction
11.15.4 InnoCore Pharmaceuticals Revenue in Sustained Release Injectables Business (2017-2022)
11.15.5 InnoCore Pharmaceuticals Recent Development
11.16 Janssen
11.16.1 Janssen Company Detail
11.16.2 Janssen Business Overview
11.16.3 Janssen Sustained Release Injectables Introduction
11.16.4 Janssen Revenue in Sustained Release Injectables Business (2017-2022)
11.16.5 Janssen Recent Development
11.17 Merck
11.17.1 Merck Company Detail
11.17.2 Merck Business Overview
11.17.3 Merck Sustained Release Injectables Introduction
11.17.4 Merck Revenue in Sustained Release Injectables Business (2017-2022)
11.17.5 Merck Recent Development
11.18 NanOlogy
11.18.1 NanOlogy Company Detail
11.18.2 NanOlogy Business Overview
11.18.3 NanOlogy Sustained Release Injectables Introduction
11.18.4 NanOlogy Revenue in Sustained Release Injectables Business (2017-2022)
11.18.5 NanOlogy Recent Development
11.19 Novartis
11.19.1 Novartis Company Detail
11.19.2 Novartis Business Overview
11.19.3 Novartis Sustained Release Injectables Introduction
11.19.4 Novartis Revenue in Sustained Release Injectables Business (2017-2022)
11.19.5 Novartis Recent Development
11.20 Oakwood Laboratories/PharmaSophia
11.20.1 Oakwood Laboratories/PharmaSophia Company Detail
11.20.2 Oakwood Laboratories/PharmaSophia Business Overview
11.20.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Introduction
11.20.4 Oakwood Laboratories/PharmaSophia Revenue in Sustained Release Injectables Business (2017-2022)
11.20.5 Oakwood Laboratories/PharmaSophia Recent Development
11.21 OctoPlus
11.21.1 OctoPlus Company Detail
11.21.2 OctoPlus Business Overview
11.21.3 OctoPlus Sustained Release Injectables Introduction
11.21.4 OctoPlus Revenue in Sustained Release Injectables Business (2017-2022)
11.21.5 OctoPlus Recent Development
11.22 Pacira
11.22.1 Pacira Company Detail
11.22.2 Pacira Business Overview
11.22.3 Pacira Sustained Release Injectables Introduction
11.22.4 Pacira Revenue in Sustained Release Injectables Business (2017-2022)
11.22.5 Pacira Recent Development
11.23 PhaseBio Pharmaceuticals
11.23.1 PhaseBio Pharmaceuticals Company Detail
11.23.2 PhaseBio Pharmaceuticals Business Overview
11.23.3 PhaseBio Pharmaceuticals Sustained Release Injectables Introduction
11.23.4 PhaseBio Pharmaceuticals Revenue in Sustained Release Injectables Business (2017-2022)
11.23.5 PhaseBio Pharmaceuticals Recent Development
11.24 Recipharm AB
11.24.1 Recipharm AB Company Detail
11.24.2 Recipharm AB Business Overview
11.24.3 Recipharm AB Sustained Release Injectables Introduction
11.24.4 Recipharm AB Revenue in Sustained Release Injectables Business (2017-2022)
11.24.5 Recipharm AB Recent Development
11.25 Roche
11.25.1 Roche Company Detail
11.25.2 Roche Business Overview
11.25.3 Roche Sustained Release Injectables Introduction
11.25.4 Roche Revenue in Sustained Release Injectables Business (2017-2022)
11.25.5 Roche Recent Development
11.26 Sanofi
11.26.1 Sanofi Company Detail
11.26.2 Sanofi Business Overview
11.26.3 Sanofi Sustained Release Injectables Introduction
11.26.4 Sanofi Revenue in Sustained Release Injectables Business (2017-2022)
11.26.5 Sanofi Recent Development
11.27 Taiwan Liposome Company (TLC)
11.27.1 Taiwan Liposome Company (TLC) Company Detail
11.27.2 Taiwan Liposome Company (TLC) Business Overview
11.27.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Introduction
11.27.4 Taiwan Liposome Company (TLC) Revenue in Sustained Release Injectables Business (2017-2022)
11.27.5 Taiwan Liposome Company (TLC) Recent Development
11.28 Xbrane Biopharma
11.28.1 Xbrane Biopharma Company Detail
11.28.2 Xbrane Biopharma Business Overview
11.28.3 Xbrane Biopharma Sustained Release Injectables Introduction
11.28.4 Xbrane Biopharma Revenue in Sustained Release Injectables Business (2017-2022)
11.28.5 Xbrane Biopharma Recent Development
11.29 Livzon Pharm
11.29.1 Livzon Pharm Company Detail
11.29.2 Livzon Pharm Business Overview
11.29.3 Livzon Pharm Sustained Release Injectables Introduction
11.29.4 Livzon Pharm Revenue in Sustained Release Injectables Business (2017-2022)
11.29.5 Livzon Pharm Recent Development
11.30 Luye Pharma Group
11.30.1 Luye Pharma Group Company Detail
11.30.2 Luye Pharma Group Business Overview
11.30.3 Luye Pharma Group Sustained Release Injectables Introduction
11.30.4 Luye Pharma Group Revenue in Sustained Release Injectables Business (2017-2022)
11.30.5 Luye Pharma Group Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
